BioMarin stops mid-stage trials of bone disorder treatment

BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases ​of patients' hip joint slipping out of ‌place, the drugmaker said on Monday, sending its shares down 4%.